{'fraction_non_alphanumeric': 0.019590382902938557, 'fraction_numerical': 0.0026714158504007124, 'mean_word_length': 5.497109826589595, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy.

BACKGROUND
An efficacious treatment is needed for human immunodeficiency virus (HIV)-infected and uninfected patients with progressive multifocal leukoencephalopathy (PML).


OBJECTIVE
To report clinical and magnetic resonance imaging changes in response to mirtazapine treatment in HIV-positive patients with PML.


DESIGN
Case series.


SETTING
Outpatient neurology clinic.


PATIENTS
Four HIV-positive patients with PML.


INTERVENTIONS
Mirtazapine use, 15 mg nightly.


MAIN OUTCOME MEASURES
Neurologic examinations and cranial magnetic resonance imaging.


RESULTS
Three patients demonstrated objective clinical improvement, and 1 patient showed improvement on magnetic resonance imaging. The patient who experienced the most significant clinical improvement was the patient who received mirtazapine therapy closest to PML symptom onset. Mirtazapine use was safe and well tolerated.


CONCLUSION
Mirtazapine use may offer some benefit as treatment or prophylaxis for PML in patients with HIV infection.